Recently, small-molecule allosteric modulators of PDE4D that do not completely inhibit enzymatic activity were reported to reduce emesis and to have therapeutic benefit for brain distribution, such as Alzheimer's disease, Huntington's disease, schizophrenia, and depression [57]. Here, PDE4D is linked to depressive disorder.